Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F15%3A33158488" target="_blank" >RIV/61989592:15310/15:33158488 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.tandfonline.com/doi/abs/10.1517/13543776.2015.1056737?journalCode=ietp20#.VuFHCvnhC70" target="_blank" >http://www.tandfonline.com/doi/abs/10.1517/13543776.2015.1056737?journalCode=ietp20#.VuFHCvnhC70</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/13543776.2015.1056737" target="_blank" >10.1517/13543776.2015.1056737</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Popis výsledku v původním jazyce

Introduction: Deubiquitinating-enzymes (DUBs) are key components of the ubiquitin-proteasome system (UPS). The fundamental role of DUBs is specific removal of ubiquitin from substrates. DUBs contribute to activation/deactivation, recycling and localization of numerous regulatory proteins, and thus play major roles in diverse cellular processes. Altered DUB activity is associated with a multitudes of pathologies including cancer. Therefore, DUBs represent novel candidates for target-directed drug development.Areas covered: The article is a thorough review/accounting of patented compounds targeting DUBs and stratifying/classifying the patented compounds based on: chemical-structures, nucleic-acid compositions, modes-of-action, and targeting sites. The review provides a brief background on the UPS and the involvement of DUBs. Furthermore, methods for assessing efficacy and potential pharmacological utility of DUB inhibitor (DUBi) are discussed.Expert opinion: The FDA's approval of the 20S

Název v anglickém jazyce

Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Popis výsledku anglicky

Introduction: Deubiquitinating-enzymes (DUBs) are key components of the ubiquitin-proteasome system (UPS). The fundamental role of DUBs is specific removal of ubiquitin from substrates. DUBs contribute to activation/deactivation, recycling and localization of numerous regulatory proteins, and thus play major roles in diverse cellular processes. Altered DUB activity is associated with a multitudes of pathologies including cancer. Therefore, DUBs represent novel candidates for target-directed drug development.Areas covered: The article is a thorough review/accounting of patented compounds targeting DUBs and stratifying/classifying the patented compounds based on: chemical-structures, nucleic-acid compositions, modes-of-action, and targeting sites. The review provides a brief background on the UPS and the involvement of DUBs. Furthermore, methods for assessing efficacy and potential pharmacological utility of DUB inhibitor (DUBi) are discussed.Expert opinion: The FDA's approval of the 20S

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion on Therapeutic Patents

ISSN

1354-3776

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

18

Strana od-do

1191-1208

Kód UT WoS článku

000369387300002

EID výsledku v databázi Scopus

—